Also, slide #24 in ENTA’s new slide set reveals new MoA and other info about EDP-721, the small-molecule HBV RNA destablizer that ENTA hopes will be the third drug in an all-oral functional cure.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”